Evicenter
Xtandi (enzalutamide) in Castration-resistant prostate cancer
Manufacturer
Astellas Pharma US, Inc.; Pfizer Inc.
Prescribing information
Xtandi (opens in a new tab)
Questions
20
Last updated

All questions

Clinical trials: Xtandi (enzalutamide) in castration-resistant prostate cancer

12 questions · 5 sources

Study results

How much does Xtandi delay metastasis vs placebo in nonmetastatic CRPC (PROSPER)?

Applies to Non-metastatic castration-resistant prostate cancer (PROSPER)

Note: In the Prescribing Information table rows, the first value is XTANDI (N = 933) and the second is placebo (N = 468).

Xtandi in nonmetastatic CRPC: do patients live longer than with placebo (PROSPER)?

Applies to Non-metastatic castration-resistant prostate cancer (PROSPER)

Note: In the Prescribing Information table rows, the first value is XTANDI (N = 933) and the second is placebo (N = 468).

Does Xtandi delay new cancer therapy in nonmetastatic CRPC (PROSPER)?

Applies to Non-metastatic castration-resistant prostate cancer (PROSPER)

Xtandi in metastatic CRPC before chemotherapy: do patients live longer (PREVAIL)?

Applies to Chemotherapy-naive metastatic castration-resistant prostate cancer (PREVAIL)

Note: The comparison is XTANDI plus GnRH therapy (or after bilateral orchiectomy) vs placebo plus GnRH therapy in chemotherapy-naive patients with metastatic CRPC. In Table 10 of the Prescribing Information, HR 0.71 is from the pre-specified interim analysis, and HR 0.77 with medians of 35.3 and 31.3 months is from the updated survival analysis; in each table row the first value is XTANDI (N = 872) and the second is placebo (N = 845).

How much does Xtandi delay radiographic progression vs placebo before chemotherapy (PREVAIL)?

Applies to Chemotherapy-naive metastatic castration-resistant prostate cancer (PREVAIL)

Note: The comparison is XTANDI plus GnRH therapy (or after bilateral orchiectomy) vs placebo plus GnRH therapy in chemotherapy-naive patients with metastatic CRPC.

Does Xtandi delay the need for chemotherapy in metastatic CRPC (PREVAIL)?

Applies to Chemotherapy-naive metastatic castration-resistant prostate cancer (PREVAIL)

How did time to first skeletal-related event compare for Xtandi vs placebo (PREVAIL)?

Applies to Chemotherapy-naive metastatic castration-resistant prostate cancer (PREVAIL)

Does Xtandi improve survival after docetaxel in metastatic CRPC (AFFIRM)?

Applies to Metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy (AFFIRM)

Note: In the Prescribing Information table rows, the first value is XTANDI (N = 800) and the second is placebo (N = 399).

How did radiographic progression-free survival compare for Xtandi vs bicalutamide in TERRAIN?

Applies to Chemotherapy-naive metastatic castration-resistant prostate cancer, compared with bicalutamide (TERRAIN)

Note: This is the radiographic progression-free survival result that the efficacy page and the Prescribing Information report. The milestones page lists progression-free survival (ICR), defined in the last passage, as the TERRAIN primary endpoint.

Clinical trials

Who was enrolled in the Xtandi PROSPER trial for nonmetastatic CRPC?

Applies to Non-metastatic castration-resistant prostate cancer (PROSPER)

Who was enrolled in the Xtandi PREVAIL trial for metastatic CRPC?

Applies to Chemotherapy-naive metastatic castration-resistant prostate cancer (PREVAIL)

Who was enrolled in the Xtandi AFFIRM trial?

Applies to Metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy (AFFIRM)